UNC Lineberger physicians, researchers to share study findings, clinical expertise at ASCO Annual Meeting 2017

UNC Lineberger physicians and researchers will present their study findings at the 2017 American Society of Clinical Oncology Annual Meeting, which is expected to draw thousands of people to Chicago this weekend.

University of North Carolina Lineberger Comprehensive Cancer Center physicians and scientists will present research findings and share expertise at the American Society of Clinical Oncology’s Annual Meeting in Chicago, June 2-6.

The meeting is expected to draw more than 30,000 oncologists and other medical professionals from the around the world.

Some of the talks and posters that will feature UNC Lineberger research include:

Saturday, June 3

Ronald C. Chen, Chair, Clinical Science Symposium, “How Can Value Frameworks Be Used to Help Patients? Practical Challenges for the Oncologist.”

Anureet Copeland, Poster Session, “Prevalence of depression and anxiety in older patients with multiple myeloma in North Carolina: A population-based, claims-based assessment.”

Daniel P. Lindsay, Poster Session, “Prospective characterization of circulating tumor cells using a nanotechnology-based capture system in oligometastatic patients undergoing definitive radiation therapy.”

Stergios J. Moschos, Poster Session, “NCI 9922: Phase 2 study of ibrutinib in treatment-refractory distant metastatic cutaneous melanoma (DMCM).”

Tomohiro Nishijima, Poster Session, “Chemotherapy toxicity risk score (CTRS) for treatment decision in older patients with advanced solid cancer.”

Kevin A. Pearlstein, Poster Session, “Cardiovascular disease and preventive care among cancer survivors: A population-based study.”

Sunday, June 4

Carey K. Anders, Poster Session, “A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB).”

Carey K. Anders, Poster Discussion Session, “LCCC 1025: Phase II study of everolimus, trastuzumab, and vinorelbine for HER2+ breast cancer brain metastases (BCBM).”

Steven Angus, Poster Session, “TBCRC 036: Window of opportunity clinical trial reveals adaptive kinome reprogramming in single and combination HER2-targeting in breast cancer (BrCa).”

Ethan M. Basch, Plenary Session, “Overall survival results of a randomized trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment.”

Stergios J. Moschos, Oral Abstract Session, “Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204.”

Stergios J. Moschos, Oral Abstract Session, “COMBI-MB: A phase II study of combination dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant (mut) melanoma brain metastases (MBM).”

Maki Tanioka, Poster Session, “Genetic causes of resistance to entinostat in luminal breast cancer model systems.”

Benjamin Vincent, Poster Session, “LCCC 1525: Combination immunotherapy with cyclophosphamide plus pembrolizumab in patients with advanced triple negative breast cancer (TNBC).”

Monday, June 5

Brittaney-Belle Gordon, Poster Discussion Session, “Factors influencing prostate cancer treatment decisions for African American (AA) and Caucasian (CA) men.”

Bhishamjit Chera, Poster Session, “Two-year clinical outcomes of de-intensified chemoradiotherapy for low-risk HPV-associated oropharyngeal squamous cell carcinoma.”

Natalie Grover, Poster Session, “Significance of MYC rearrangement and chemotherapy type on survival outcomes of patients with central nervous system lymphoma.”

Federico Innocenti, Oral Abstract Session, “Somatic DNA mutations, MSI status, mutational load (ML): Association with overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 (Alliance).”

Stergios J. Moschos, Poster Session, “Phase 1 study of the p53-MDM2 inhibitor AMG 232 combined with trametinib plus dabrafenib or trametinib in patients (Pts) with TP53 wild type (TP53WT) metastatic cutaneous melanoma (MCM).”

Grace Prince, Poster Session, “Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases.”

Siddharth Sheth, Poster Session, “Population assessment of head and neck cancer outcomes by race and HPV status in chance.”

Jared Weiss, Poster Session, “Multimodality risk adapted therapy with induction carboplatin/paclitaxel/lapatinib for SCCHN amenable to transoral surgery.”

Tuesday, June 6

Lisa A. Carey, Highlights of the Day, “Breast Cancer—Local/Regional/Adjuvant”